The Fertility Partnership (“TFP”) is one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments with 10 fertility clinics in the UK and Poland. TFP was acquired by Impilo in March 2019
VivaNeo GmbH (“VivaNeo”) is one of the leading European providers of fertility services, with 9 fertility clinics across Austria, Denmark, Netherlands and Germany employing ~300
The combined group will deliver superior patient experience across 19 clinics in 6 counties and deliver ~24,000 cycles and 110 million EUR revenues annually
Impilo is excited about the acquisition of VivaNeo supporting the strategy of building the pan-European fertility leader
The Fertility Partnership has today signed an agreement to acquire VivaNeo GmbH from Waterland Private Equity. VivaNeo is one of the leading European providers of fertility services with 9 clinics supported by 5 satellite clinics across Germany, Austria, Denmark and the Netherlands. The group includes a blood diagnostics laboratory in Germany servicing the local market and some international clinics, as well as a dialysis business in Germany.
In 2011, the first VivaNeo clinic was acquired in Wiesbaden. Between 2011 and 2014, the group expanded in Germany and the Netherlands with clinics added in Berlin, Dusseldorf and Leiderdorp. From 2015 to 2019 the group rapidly expanded acquiring 3 clinics in Austria and 2 in Denmark.
Since its inception, the group’s focus has been on the provision of best-in-class patient experience supported by scientific and clinical excellence. VivaNeo now delivers ~14,000 cycles annually, with revenues of approximately €50m million and ~300 full-time employees.
We are excited and delighted to welcome the VivaNeo team to The Fertility Partnership family. There is a strong cultural compatibility between the groups both being absolutely focused focus on providing best in class fertility treatments and patient care during the IVF journey. Together, through an expansive network of like-minded professionals, we will be able to further improve patient experience and success rates through broader investment in research and technology.”
- Andrew Came, CEO of TFP.
The Impilo team is excited about the investment:
Through this investment we are a step closer to our vision of creating the pan-European leader in the provision of fertility services. We are highly impressed with VivaNeo’s excellent clinical and scientific standing in the community alongside their unwavering commitment to superior patient experience. We are looking forward to actively supporting the growth and development of the combined group and more broadly contributing to the development of the fertility industry.”
– says Hans-Christian Bødker Jensen, responsible Partner at Impilo.
The Fertility Partnership is a leading European provider of fertility services, ultrasound pregnancy scans and hormone treatments present in the UK and in Poland. The group comprises 8 IVF clinics in the UK, 2 IVF clinics in Poland, 88 ultrasound clinics in the UK, as well as a nascent hormone treatment business. TFP was founded in 2012 through the merger of two IVF clinics and has since expanded through further add-on acquisitions, greenfield developments and expansion into adjacent services. Today it is the largest provider of fertility services in the UK and the third largest in Poland; it also operates the UK’s leading independent provider of ultrasound scanning services. Learn more about TFP at https://www.thefertilitypartnership.com/
Viva Neo is a leading European provider of fertility services, present in Germany, Austria, the Netherlands and Denmark. The group comprises 9 IVF clinics across four countries, an egg donor bank, as well as a blood diagnostic laboratory and a dialysis centre in Germany. It holds the number 1 or 2 market position in market share terms in each of its markets. The group focus is on best-in-class patient experience and success rates.
Learn more about Viva Neo at https://vivaneo-ivf.com/en/
Impilo is a Nordic-based investment company focused on investments in healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. Impilo’s perspective is that the portfolio companies must contribute to a positive development in their fields and thus society in order to be successful long term. Impilo manages over SEK 3.5 billion in capital from leading Nordic and international investors. Larger investors include AP3 (The Third Swedish National Pension Fund), Tryghedsgruppen and Goldman Sachs Asset Management. Learn more about Impilo at www.impilo.se.